592 related articles for article (PubMed ID: 26939704)
21. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
Osman HM; Tuncbilek M
Curr Med Chem; 2022; 29(15):2602-2616. PubMed ID: 34521321
[TBL] [Abstract][Full Text] [Related]
22. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
23. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
MacFarland SP; Naraparaju K; Iyer R; Guan P; Kolla V; Hu Y; Tan K; Brodeur GM
Mol Cancer Ther; 2020 Mar; 19(3):920-926. PubMed ID: 31871269
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
[TBL] [Abstract][Full Text] [Related]
27. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Yun MR; Kim DH; Kim SY; Joo HS; Lee YW; Choi HM; Park CW; Heo SG; Kang HN; Lee SS; Schoenfeld AJ; Drilon A; Kang SG; Shim HS; Hong MH; Cui JJ; Kim HR; Cho BC
Clin Cancer Res; 2020 Jul; 26(13):3287-3295. PubMed ID: 32269053
[TBL] [Abstract][Full Text] [Related]
28. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
29. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
[TBL] [Abstract][Full Text] [Related]
31. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
32. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
33. Entrectinib, a new multi-target inhibitor for cancer therapy.
Jiang Q; Li M; Li H; Chen L
Biomed Pharmacother; 2022 Jun; 150():112974. PubMed ID: 35447552
[TBL] [Abstract][Full Text] [Related]
34. Evaluating entrectinib as a treatment option for non-small cell lung cancer.
Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Opin Pharmacother; 2020 Nov; 21(16):1935-1942. PubMed ID: 32736487
[TBL] [Abstract][Full Text] [Related]
35. Foretinib Overcomes Entrectinib Resistance Associated with the
Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
[No Abstract] [Full Text] [Related]
36. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.
Amatu A; Somaschini A; Cerea G; Bosotti R; Valtorta E; Buonandi P; Marrapese G; Veronese S; Luo D; Hornby Z; Multani P; Murphy D; Shoemaker R; Lauricella C; Giannetta L; Maiolani M; Vanzulli A; Ardini E; Galvani A; Isacchi A; Sartore-Bianchi A; Siena S
Br J Cancer; 2015 Dec; 113(12):1730-4. PubMed ID: 26633560
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
38. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473
[TBL] [Abstract][Full Text] [Related]
39. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
Araujo JM; Gomez AC; Pinto JA; Rolfo C; Raez LE
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):192-198. PubMed ID: 33290717
[TBL] [Abstract][Full Text] [Related]
40. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.
Ou SH; Tan J; Yen Y; Soo RA
Expert Rev Anticancer Ther; 2012 Apr; 12(4):447-56. PubMed ID: 22500682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]